What is it that makes the Indian middle class treat their domestic help with such derision and abuse? In her nine years as a nurse working with rescued domestic workers in Delhi, Mariamma K. thought she had seen the worst. That was until 2010, when she and her colleagues went to rescue a 17-year-old girl from a home in west Delhi. Sangeeta was found with bite marks all over her body....

Deng Xiaoping, the architect of modern China, had a sharp, snappy way of putting across what he wanted to say. Some of his eminently quotable quotes include: “It doesn’t matter if the cat is black or white so long as it catches mice” and “Poverty is not socialism. To be rich is glorious”. But there’s another, less well-known and even more controversial quote also attributed to him: “Let some people...

India, like other Asian countries, has focused its climate change adaptation strategies on rural and urban areas while neglecting the urban fringes, say experts. Peri-urban areas are characterised by haphazard, accelerated expansion and are farthest from basic urban services and infrastructure, according to United Nations-Habitat’s ‘The State of Asian Cities 2010-11’. By 2020, of the projected 4.2 billion urban population of the world, 2.2 billion will be living in Asia, many...

-Economic and Political Weekly The compulsory licence for Nexavar is only the beginning of a new battle over drug prices. The grant of a compulsory licence (CL) to Natco Pharma, a relatively small Indian pharmaceutical company, to manufacture and sell the cancer drug sorafenib (Nexavar) has been rightly hailed as a major step forward for public health and the wider availability of life saving medicines.   The German pharmaceutical company Bayer holds the patent...

India's decision this month to produce Germany-based multinational Bayer's anti-cancer drug Nexavar, in the first use of "compulsory licensing" in South Asia, will save lives but also raises intricate questions. Under the compulsory licensing process, a government can under World Trade Organization (WTO) rules bypass a patent owner's rights after three years and order the manufacture and sale of life-saving medicines at much cheaper cost than by obtaining the medicine from...